SERTRA keeps serotonin in the conversation.

SERTRA keeps serotonin in the conversation.

Selected depressive and anxiety-related disorders. Inhibits serotonin reuptake. Key safety: Serotonin syndrome, discontinuation effects and other patient-specific warnings. Monitor: Clinical response, suicidality where indicated and serotonergic combinations. Counseling: Avoid abrupt self-discontinuation; report concerning agitation, fever or rigidity.

A patient taking sertraline adds another strongly serotonergic drug and develops agitation, fever and clonus. Which syndrome is concerning?

A. Serotonin syndrome.

B. SSRI discontinuation syndrome despite adding rather than stopping a serotonergic drug.

C. A harmless expected increase in antidepressant effectiveness.

D. Isolated anticholinergic dry mouth without a need to assess the systemic findings.

SERTRA keeps serotonin in the conversation.

SERTRA keeps serotonin in the conversation.

Selected depressive and anxiety-related disorders. Inhibits serotonin reuptake. Key safety: Serotonin syndrome, discontinuation effects and other patient-specific warnings. Monitor: Clinical response, suicidality where indicated and serotonergic combinations. Counseling: Avoid abrupt self-discontinuation; report concerning agitation, fever or rigidity.

A patient taking sertraline adds another strongly serotonergic drug and develops agitation, fever and clonus. Which syndrome is concerning?

A. Serotonin syndrome.

B. SSRI discontinuation syndrome despite adding rather than stopping a serotonergic drug.

C. A harmless expected increase in antidepressant effectiveness.

D. Isolated anticholinergic dry mouth without a need to assess the systemic findings.

SERTRA keeps serotonin in the conversation.

SERTRA keeps serotonin in the conversation.

Selected depressive and anxiety-related disorders. Inhibits serotonin reuptake. Key safety: Serotonin syndrome, discontinuation effects and other patient-specific warnings. Monitor: Clinical response, suicidality where indicated and serotonergic combinations. Counseling: Avoid abrupt self-discontinuation; report concerning agitation, fever or rigidity.

A patient taking sertraline adds another strongly serotonergic drug and develops agitation, fever and clonus. Which syndrome is concerning?

A. Serotonin syndrome.

B. SSRI discontinuation syndrome despite adding rather than stopping a serotonergic drug.

C. A harmless expected increase in antidepressant effectiveness.

D. Isolated anticholinergic dry mouth without a need to assess the systemic findings.

SERTRA keeps serotonin in the conversation.

SERTRA keeps serotonin in the conversation.

Selected depressive and anxiety-related disorders. Inhibits serotonin reuptake. Key safety: Serotonin syndrome, discontinuation effects and other patient-specific warnings. Monitor: Clinical response, suicidality where indicated and serotonergic combinations. Counseling: Avoid abrupt self-discontinuation; report concerning agitation, fever or rigidity.

A patient taking sertraline adds another strongly serotonergic drug and develops agitation, fever and clonus. Which syndrome is concerning?

A. Serotonin syndrome.

B. SSRI discontinuation syndrome despite adding rather than stopping a serotonergic drug.

C. A harmless expected increase in antidepressant effectiveness.

D. Isolated anticholinergic dry mouth without a need to assess the systemic findings.